Tumor deposits at the fusion of the right and left gastric mesenteries after proximal gastrectomy
Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy With D2 Lymphadenectomy Plus Complete Mesogastric Excision for Gastric Cancer: A Prospective Observational Study
We will see if tumor tissue is present at the fusion site between the right and left gastric mesenteries in adults having proximal gastrectomy for gastric cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06728891 on ClinicalTrials.gov |
What this trial studies
This observational, single-center study will examine surgical specimens from adults with primary gastric adenocarcinoma who undergo proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision. Investigators will inspect the fusion site between the right and left gastric mesenteries and document any tumor deposits using standard pathological methods. Eligible patients are clinical stage cT2–4aN0–3M0, aged 18–85, ASA class I–III, without prior neoadjuvant therapy or previous upper abdominal surgery. The study aims to generate evidence on whether current dissection patterns may leave residual tumor at the mesenteric fusion and to inform standardized lymph node clearance recommendations.
Who should consider this trial
Good fit: Ideal candidates are adults 18–85 years old with primary gastric adenocarcinoma staged cT2–4aN0–3M0 who are planned for proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision, have ASA class I–III, BMI ≤30 kg/m2, and have not received neoadjuvant therapy.
Not a fit: Patients with metastatic disease (cT4b/M1), prior neoadjuvant chemotherapy or radiotherapy, previous upper abdominal surgery, other active malignancies, BMI >30 kg/m2, or those who refuse surgery are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If tumor deposits are identified at the fusion site, the findings could prompt modifications to surgical lymph node clearance and potentially reduce local recurrence after proximal gastrectomy.
How similar studies have performed: Work on complete mesogastric excision and extended lymphadenectomy exists, but direct study of tumor deposits at the right–left gastric mesenteric fusion site is limited and relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged older than 18 years and younger than 85 years 2. Primary gastric adenocarcinoma confirmed by preoperative pathology result 3. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition 4. Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision 5. American Society of Anesthesiologists (ASA) class I, II, or III 6. Written informed consent Exclusion Criteria: 1. Negative preoperative biopsy 2. Too late tumour stage or metastasis (cT4b/M1) 3. BMI\>30 kg/m2 4. previous neoadjuvant chemotherapy or radiotherapy 5. Previous upper abdominal surgery 6. Combined with other malignant diseases 7. Reject operation
Where this trial is running
Hangzhou, Zhejiang
- Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Tao Wang, Ph.d
- Email: 15002740874@163.com
- Phone: +86-197-068-25286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.